MaxCyte

Gaithersburg, MD
Platform Provider
CAR-T Cell Therapy
Program data pending ClinicalTrials.gov matching · Last scored 2026-04-02
60.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (15) ○ EMA GMP ○ MHRA GMP

Quick Facts: MaxCyte

Signal Score
60.5/100 (as of 2026-04-02)
Quality Compliance
Assessment pending
Headquarters
Gaithersburg, MD
Modalities
CAR-T, Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 63.0
M&A activity detected (1 articles)
Active fundraising/financial news (4 articles)
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
M&A activity detected (1 articles)
Active fundraising/financial news (4 articles)
Capacity 58.0
1 manufacturing site: Gaithersburg, MD
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Gaithersburg, MD
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
Recent Press15 articles
1 manufacturing site: Gaithersburg, MD
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100

Recent News 15 articles

regulatory 2026-03-26
MaxCyte's $136M Fortress Balance Sheet Masks a $4M Structural Headwind as ExPERT DTx Pivot Tests 2026 Inflection - Bitget
MaxCyte's $136M Fortress Balance Sheet Masks a $4M Structural Headwind as ExPERT DTx Pivot Tests 2026 Inflection  Bitget
Source →
general 2026-03-26
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development - Minichart
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development  Minichart
Source →
financial 2026-03-25
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1 - Minichart
MaxCyte Reports 2025 Financial Results, Announces 2026 Revenue Guidance and Expansion in Cell Therapy Platform 1  Minichart
Source →
general 2026-03-25
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside - Stock Titan
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside  Stock Titan
Source →
financial 2026-03-24
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - The Globe and Mail
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript  theglobeandmail.com
Source →
financial 2026-03-24
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript - AOL.com
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript  AOL.com
Source →
financial 2026-03-24
MaxCyte Q4 Earnings Call Highlights - MarketBeat
MaxCyte Q4 Earnings Call Highlights  MarketBeat
Source →
general 2026-03-23
Agilent investor relations veteran Parmeet Ahuja joins MaxCyte as CFO - Stock Titan
Agilent investor relations veteran Parmeet Ahuja joins MaxCyte as CFO  Stock Titan
Source →
general 2026-03-23
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer - The Manila Times
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer  The Manila Times
Source →
general 2026-03-22
MaxCyte (MXCT) Stephens 26th Annual Investment Conference | NASH2024 Summary - Quartr
MaxCyte (MXCT) Stephens 26th Annual Investment Conference | NASH2024 Summary  Quartr
Source →
general 2026-03-19
MaxCyte, Inc. $MXCT Shares Bought by Mirabella Financial Services LLP - MarketBeat
MaxCyte, Inc. $MXCT Shares Bought by Mirabella Financial Services LLP  MarketBeat
Source →
ma 2026-03-17
Mirabella Financial Services LLP Purchases 1,600,000 Shares of MaxCyte, Inc. $MXCT - MarketBeat
Mirabella Financial Services LLP Purchases 1,600,000 Shares of MaxCyte, Inc. $MXCT  MarketBeat
Source →
general 2026-03-09
MaxCyte unveils new 96-well electroporation platform to accelerate discovery - Select Science
MaxCyte unveils new 96-well electroporation platform to accelerate discovery  Select Science
Source →
general 2026-02-24
New MaxCyte lab device runs 96 cell samples in a three-minute cycle - Stock Titan
New MaxCyte lab device runs 96 cell samples in a three-minute cycle  Stock Titan
Source →
general 2026-02-24
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery - The Manila Times
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery  The Manila Times
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 90.7
CAR-T, Cell Therapy
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.9
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.5
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.9
CAR-T, Cell Therapy, AAV